Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CNTB vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (33.2 SELL vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: CNTB 4 – 1 SRZN (1 Tie) Matrix Metrics: CNTB 4 – 5 SRZN

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY).
  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both CNTB (41.0/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNTB vs SRZN
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28

6-Pillar Scorecard Institutional Category Breakdown (CNTB 4 – 1 SRZN)

Columns: Metric · CNTB · SRZN
1. Valuation Multiples CNTB
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 5.5x 48.3x
2. Growth & Scale CNTB
Revenue Growth (YoY) +5666.7% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $3.0M $11M
Market Cap $42.6M $602.5M
3. Profitability & Quality SRZN
Gross Margin 100.0% N/A
Operating Margin -2384.5% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -140.5% -62.8%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$61M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNTB
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 397.3% (100th %ile) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNTB (4) vs SRZN (5)
Institutional Metric CNTB SRZN Criterion Row Edge
Market Capitalization
Scale
$42.6M $602.5M Larger Scale SRZN
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+5666.7% +408.6% Higher Growth CNTB
Operating Margin (TTM)
Profitability
-2384.5% -485.4% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-140.5% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
1% ($1–$4) 69% ($12–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
0.92β · 68% Vol 1.28β · 66% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 33.2 / 100 (SELL) Higher Composite CNTB
Trailing 12M Revenue (USD)
Operating Scale
$3.0M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.5x EV/Rev N/M PEG · 48.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$61M ($26M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +59.79 pp
CNTB: -34.22% · SRZN: +25.57%
3M Horizon SRZN +100.62 pp
CNTB: -75.94% · SRZN: +24.68%
6M Horizon SRZN +90.04 pp
CNTB: -72.97% · SRZN: +17.07%
1Y Horizon SRZN +202.7 pp
CNTB: -72.08% · SRZN: +130.62%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CNTB Revenue SRZN Revenue CNTB Op. Margin SRZN Op. Margin Margin Leader
FY2022 N/A $10M N/A -354.7% SRZN
FY2024 $30M $10M -86.2% -239.7% CNTB
FY2025 $0M $0M -90740.6% -1210.6% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CNTB vs SRZN Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both CNTB (41.0/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), CNTB cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.